Literature DB >> 24239736

Clinical usefulness of coregistered 11C-methionine positron emission tomography/3-T magnetic resonance imaging at the follow-up of acromegaly.

Sandra Rodriguez-Barcelo1, Antonio Gutierrez-Cardo2, Miguel Dominguez-Paez3, Juan Medina-Imbroda3, Lorena Romero-Moreno3, Miguel Arraez-Sanchez3.   

Abstract

OBJECTIVE: This study sought to characterize the utility of coregistered 11C-methionine positron emission tomography (MET-PET) with 3-T magnetic resonance imaging (3T MRI) in the diagnosis and follow-up of pituitary adenomas in patients with acromegaly and to compare MET-PET and 18F-fluorodeoxyglucose emission tomography (FDG-PET) for the evaluation of active or recurrent disease.
METHODS: This is a prospective observational study. It included a total of 17 patients, 6 patients with a new diagnosis of acromegaly and 11 patients who had previously undergone resection of a confirmed growth hormone-secreting adenoma. The study protocol consisted of preoperative and postoperative evaluation with 3T MRI, and both MET-PET and FDG-PET. Coregistration of 3T MRI/MET-PET was accomplished.
RESULTS: In all patients who underwent preoperative imaging, MET-PET demonstrated increased uptake coincident with location of the pituitary lesion on 3T MRI. In the postoperative group, the coregistered 3T MRI/MET-PET demonstrated evidence of residual tumor in all patients with active disease. MET-PET sensitivity was 86% and specificity was 86% for the diagnosis of recurrence.
CONCLUSIONS: MET-PET is a sensitive technique for diagnosing persistent acromegaly, and its coregistration with 3T MRI has demonstrated a better definition of the interface, extension, and location of the lesion in the management of active postoperative acromegaly.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3T MRI; Acromegaly; Methionine; PET; Pituitary adenoma

Mesh:

Substances:

Year:  2013        PMID: 24239736     DOI: 10.1016/j.wneu.2013.11.011

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  4 in total

1.  The combination of 13N-ammonia and 11C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy.

Authors:  Fangling Zhang; Qiao He; Ganhua Luo; Yali Long; Ruocheng Li; Lei Ding; Xiangsong Zhang
Journal:  BMC Cancer       Date:  2021-07-20       Impact factor: 4.430

2.  Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery.

Authors:  Leontine E H Bakker; Marco J T Verstegen; Wouter R van Furth; Lenka M Pereira Arias Bouda; Eidrees Ghariq; Berit M Verbist; Pieter J Schutte; Waiel A Bashari; Mark C Kruit; Alberto M Pereira; Mark Gurnell; Nienke R Biermasz
Journal:  Pituitary       Date:  2022-05-26       Impact factor: 3.599

3.  Selective resection of cushing microadenoma guided by preoperative hybrid 18-fluoroethyl-L-tyrosine and 11-C-methionine PET/MRI.

Authors:  Sven Berkmann; Michel Roethlisberger; Beat Mueller; Mirjam Christ-Crain; Luigi Mariani; Egbert Nitzsche; Freimut Juengling
Journal:  Pituitary       Date:  2021-06-21       Impact factor: 4.107

4.  Cushing's Syndrome in a Patient With Rathke's Cleft Cyst and ACTH Cell Hyperplasia Detected by 11C-Methionine PET Imaging-A Case Presentation.

Authors:  Karol Piotr Sagan; Elzbieta Andrysiak-Mamos; Leszek Sagan; Przemysław Nowacki; Bogdan Małkowski; Anhelli Syrenicz
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-22       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.